Medela Gloves’ Post

The U.S. is raising tariffs on medical products imported from China, amid a broader set of tariff hikes announced by President Joe Biden on Tuesday.  The tariff rate on syringes and needles will increase from zero to 50%, and the rate for certain respirators and face masks will increase to 25% this year, from the current range of zero to 7.5%. Tariffs on rubber gloves will increase from 7.5% to 25% in 2026. The rate hikes focus on areas where the Biden administration has sought to boost domestic production, such as medical supplies that were essential to the COVID-19 pandemic response. My bigger concern is how does China respond regarding these tariffs and subsequent market access for higher value medical device imports in Structural Heart, Electrophysiology, Neurovascular, Coronary and Peripheral applications?

The U.S. is raising #tariffs on #medical devices imported from #China as part of the administration's broad-sweeping tariff hikes announced last week. With tariffs on syringes and needles jumping from 0% to 50%, and similar increases for other critical medical supplies, #manufacturers are grappling with the potential for disrupted #supplychains and increased production costs. And it comes just as manufacturers are recovering from the global supply chain crisis that plagued industry during the COVID-19 pandemic. Our #CEO Dave Evans at Fictiv comments on this latest round of challenges and how these tariffs and disruptions make the case for #digitalmanufacturing. Read more... #medicaldevices #injectionmolding #reshoring #supplychaindisruptions

📈 Impact of Biden's Tariffs on Chinese Medical Supplies The Biden Administration's tariff hikes on Chinese medical supplies aim to boost domestic manufacturing and address safety concerns. Key products affected include syringes (50% tariff), respirators and face masks (25% tariff), and rubber gloves (25% tariff by 2026). This shift could reduce dependency on Chinese imports but may lead to higher prices and potential supply chain disruptions. Domestic manufacturers are preparing to meet increased demand, yet the American Hospital Association warns these tariffs could financially strain hospitals. 🔗 Read more #Healthcare #MedicalSupplies #Tariffs #DomesticManufacturing #SupplyChain #BidenAdministration

In May 2024, President Biden made the decision to raise tariffs on various Chinese imports, including medical supplies. See a high-level breakdown of what items may be included and how it may impact your supply chain going forward. https://lnkd.in/dWdZk_Mw #healthcare #supplychain #tariffs #globalsupplychain #s2sglobal

In May 2024, President Biden made the decision to raise tariffs on various Chinese imports, including medical supplies. See a high-level breakdown of what items may be included and how it may impact your supply chain going forward. https://lnkd.in/ecjq5G94 #healthcare #supplychain #tariffs #globalsupplychain #s2sglobal

Last Friday, 9/13/24, the Office of the U.S. Trade Representative (USTR) released the final modifications to the latest round of Chinese tariff changes that were initially published in May 2024. Most items didn’t have material changes; however, exam gloves did get significant movement. Originally, a 25% tariff was scheduled to start in 2026, this was accelerated to a 50% tariff starting January 1, 2025, and 100% in 2026.  China currently has an estimated 70% of US market share, and this tariff increase will have material impacts across the industry. For instance, manufacturers outside of China have used this an opportunity to raise their prices by at least 20%+ in the last week.   The market is volatile as large suppliers shift their capacity from China to alternate countries of origin. At GCB Medical, we have a resiliency plan in place to mitigate major supply disruption events such as this. If you have questions about the impact of the tariff on gloves, please reach out to GCB Medical to schedule a call to discuss mitigation strategies: Info@gcbmedicalsupply.com   https://lnkd.in/eH776FDG

Trump’s old school protectionist (read: socialist) tariffs not only ravaged the medical supply chain at its most strained moment but also set the U.S. on course for Great Depression II. “Health supply chain experts sound the warning bell The healthcare industry warned the Trump administration long before COVID-19 that imposing tariffs on Chinese-produced essential healthcare products put the nation’s public health preparedness at risk. In August 2018, Matt Rowan, president of the Health Industry Distributors Association (HIDA) told the U.S. Trade Representative (USTR) 301 Committee that products on the proposed list were widely used in healthcare settings and ‘are a critical component of our nation’s response to public health emergencies, such as Ebola.’ Tariffs on items like masks, medical gloves, isolation gowns and wet wipes would not only increase U.S. healthcare costs, but impact government and commercial suppliers supporting patients and providers during a medical crisis, the industry warned. ‘We did not make up for the lack of imports from China by more imports from the rest of the world.’”

The US will hike tariffs on Chinese-made medical gloves to 25% from 7.5% in 2026. US president Joe Biden announced new tariffs on US$18 billion worth of Chinese imports including medical gloves to protect US industries. The shares of Malaysian glove makers surged today on news that the US has raised tariffs on Chinese-made medical gloves to 25% from 7.5%. Top Glove Corp Bhd’s shares jumped as much as 30% or 28 sen to RM1.24 in the morning trade, valuing it at almost RM9.9 billion. It was also the most heavily traded stock on Bursa Malaysia with 369.08 million shares changing hands by the midday break. In second place was Supermax Corp Bhd, which saw 210.5 million shares traded. Its share price jumped as much as 22.5% or 19.5 sen to RM1.06, giving it a market capitalisation of RM2.8 billion. Hartalega Holdings Bhd surged 29% or 86 sen to RM3.82, its highest since June 2022, valuing the group at RM13 billion. Kossan Rubber Industries Bhd was up 17.2% or 41 sen to RM2.79, valuing it at RM7.1 billion. The smaller cap glove counters also got in on the action with Careplus Group Bhd the third most active stock on Bursa Malaysia with 178.3 million shares traded. It jumped to a high of 38 sen, up 25% or 7.5 sen, valuing the company at RM258.6 million. US president Joe Biden announced yesterday new tariffs on US$18 billion (RM84.6 billion) worth of Chinese imports, including rubber medical and surgical gloves, electric vehicles, batteries, and solar cells to safeguard US industries from perceived unfair competition from China. While investors are revelling in higher prices for glove stocks, the euphoria will likely evaporate sooner rather than later. This is because the higher tariff on gloves from China will only kick in two years from now, in 2026. An analyst who covers the glove sector said today’s price action was likely a “knee-jerk reaction” and overdone. Nevertheless, Biden’s announcement is good news for Malaysia’s glove companies which have been pummeled in recent years by Chinese glove makers slashing prices, hurting their margins, profits and share prices in the process. The tariffs will ultimately increase the cost of Chinese gloves, making Malaysian gloves more attractive to American buyers, and enabling them to regain market share lost to their Chinese counterparts. RHB Investment Bank said average selling prices for Chinese gloves are set to rise to US$20-US$21.25/1,000 from US$16-US$17 due to the tariff hike, narrowing the price gap with Malaysia-made gloves, which now sell at US$20. “While the new tariffs are expected to be effective from 2026, this may allow Chinese manufacturers to reconsider their expansion plans into overseas markets to circumvent the tariff hike. “In our view, overseas expansions could make Chinese glove makers less cost competitive as manufacturers in China use coal, a cheaper fuel compared to natural gas,” it's view. Malaysian manufacturer, is time to make our economy grow further for a better Malaysia!

Supporting USA Manufacturing as USA Protective Care insures that Americans Brands are authentic and can be trusted here and abroad. The recent tariffs for medical products from China and/or foreign suppliers will be supported by companies that will be the “Trusted Brands” of American Innovation 🇺🇸 Heres an analysis of how American manufacturers could potentially benefit from trade tariffs on medical products imported from China: 1. Increased competitiveness: Tariffs on Chinese medical products could make domestically produced items more price-competitive in the U.S. market. 2. Market share growth: As imported products become more expensive, American manufacturers may be able to capture a larger share of the domestic market. 3. Reinvestment in production: Higher profits from increased sales could lead to more investment in U.S. manufacturing facilities and technologies. 4. Job creation: Expanded production could lead to more jobs in the American medical manufacturing sector. 5. Supply chain resilience: Reduced reliance on imports could strengthen the domestic supply chain for medical products. 6. Innovation incentives: Protection from foreign competition might encourage more R&D investment by U.S. companies. However, it's important to note that tariffs can have complex economic effects. They might also lead to: - Higher costs for consumers and healthcare providers - Potential retaliatory measures from China - Disruptions in global supply chains - Increased production costs if manufacturers rely on Chinese components The actual impact would depend on factors such as the specific products affected, tariff rates, market dynamics, and how both countries' industries adapt to the changes. Please support our mission of Authenticating American Innovation 🇺🇸✌🏼